Literature DB >> 8258188

Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations.

J J Reilly1, P Workman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8258188     DOI： 10.1007/bf00685883

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  32 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.

Authors:  J P Hale; J S Lilleyman
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

Review 3.  The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies.

Authors:  M A Graham; P Workman
Journal:  Ann Oncol       Date:  1992-05       Impact factor: 32.976

4.  Comparative metabolism of tritiated water by mammals.

Authors:  C R RICHMOND; W H LANGHAM; T T TRUJILLO
Journal:  J Cell Comp Physiol       Date:  1962-02

5.  Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.

Authors:  M J Ratain; R Mick; R L Schilsky; N J Vogelzang; F Berezin
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

6.  Is dose normalization to weight or body surface area useful in adults?

Authors:  L B Grochow; C Baraldi; D Noe
Journal:  J Natl Cancer Inst       Date:  1990-02-21       Impact factor: 13.506

Review 7.  Predicting energy requirements: is energy expenditure proportional to the BMR or to body weight? An analysis of data collected in rural Gambian women.

Authors:  M Lawrence
Journal:  Eur J Clin Nutr       Date:  1988-11       Impact factor: 4.016

8.  Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.

Authors:  L Gianni; L Viganò; A Surbone; D Ballinari; P Casali; C Tarella; J M Collins; G Bonadonna
Journal:  J Natl Cancer Inst       Date:  1990-03-21       Impact factor: 13.506

9.  Human surface area: comparison of the Du Bois formula with direct photometric measurement.

Authors:  D Mitchell; N B Strydom; C H van Graan; W H van der Walt
Journal:  Pflugers Arch       Date:  1971       Impact factor: 3.657

10.  6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity.

Authors:  S Hayder; P Lafolie; O Björk; C Peterson
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681
View more
  21 in total

Review 1.  Common errors of drug administration in infants: causes and avoidance.

Authors:  B J Anderson; J F Ellis
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

Review 3.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Relationships among liver and kidney volumes, lean body mass and drug clearance.

Authors:  S Nawaratne; J E Brien; E Seeman; R Fabiny; J Zalcberg; W Cosolo; P Angus; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

5.  Dose standardisation of anticancer drugs.

Authors:  Anne-Lise Pouliquen; Laurence Escalup; Nathalie Jourdan; Paul Cottu; Pierre Faure; Isabelle Madelaine-Chambrin
Journal:  Int J Clin Pharm       Date:  2011-01-14

Review 6.  Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.

Authors:  J J Reilly; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Chemotherapy dosing in overweight and obese patients with cancer.

Authors:  Gary H Lyman; Alex Sparreboom
Journal:  Nat Rev Clin Oncol       Date:  2013-07-16       Impact factor: 66.675

8.  Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.

Authors:  Ahmed F Hawwa; Paul S Collier; Jeff S Millership; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

Review 9.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 10.  Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.

Authors:  P Canal; E Gamelin; G Vassal; J Robert
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.